Where does Syndax Pharmaceuticals's cash flow data come from?

Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$243.25M+26.6%	-$285.42M+10.5%	-$311.58M-4.9%	-$334.99M-26.8%	-$331.2M-37.6%
Stock-based compensation	$49.18M+10.5%	$47.5M+10.4%	$48.55M+24.3%	$48.4M+36.6%	$44.51M+32.4%
Amortization of debt issuance costs	$173K+21.8%	$229K+663%	$259K—	$197K—	$142K—
Change in accounts receivable	$22.15M+40.9%	$30.39M+300%	$25.4M—	$19.45M—	$15.72M—
Change in inventories	$29.96M+557%	$32.09M+8,668%	$24.66M—	$17.47M—	$4.56M—
Change in accounts payable	——	——	——	$5.79M—	$1.24M—
Change in accrued liabilities	$16.35M-29.9%	$42.17M+120%	$28.13M+87.7%	$48.06M+493%	$23.32M+34.5%
Change in other assets	$12.7M—	$14.54M—	——	——	——
Change in other current assets	——	——	——	——	——
Change in receivables	$344K—	$6.44M—	$160K—	——	——
Net cash from operating activities	-$278.16M+2.9%	-$322.98M-17.5%	-$310.88M-20.1%	-$302.67M-25.5%	-$286.52M-39.8%
Purchases of investments	$224.66M-43.9%	$195.81M-64.8%	$509.01M+64.2%	$491.92M+29.7%	$400.21M-13.1%
Proceeds from maturities/sales of investments	$459.13M+22.8%	$486.03M+44.1%	$448.62M+30.8%	$445.82M+22.0%	$373.97M-18.5%
Net cash from investing activities	$234.28M—	$290.04M—	-$60.52M—	-$46.1M—	——
Net cash from financing activities	$20.66M-94.1%	$13.68M-96.1%	$355.18M+34.3%	$352M+33.8%	$352.13M+33.5%
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$8.02M-39.5%	$10.75M-20.2%	$12.16M-13.0%	$12.81M-12.2%	$13.25M-9.6%
Amortization expense related to capitalized debt issuance costs	$173K+21.8%	$229K+663%	$259K—	$197K—	$142K—
Depreciation And Related Adjustment	$10K+100%	$6K-25.0%	$3K-72.7%	$2K-83.3%	$5K-58.3%
Increase (Decrease) in Accounts Receivable and Other Operating Assets	$344K—	$6.44M—	$160K—	——	——
Accrued expenses and other liabilities	$16.35M-29.9%	$42.17M+120%	$28.13M+87.7%	$48.06M+493%	$23.32M+34.5%
Increase Decrease In Collaboration Receivable	-$32.69M-805%	-$42.98M-458%	-$21.24M—	-$15.42M—	$4.64M—
Increase (Decrease) in Prepaid Expense and Other Assets	$12.7M—	$14.54M—	——	——	——
Inventory Reserves	——	$163K—	$122.25K—	$81.5K—	$40.75K—
Noncash Operating Lease Expense	$855K-11.5%	$946K-4.3%	$759K-25.9%	$896K-7.2%	$966K+10.7%
Allowance for credit losses	——	$3.67M—	$2.75M—	——	——
Payments to Acquire Short-Term Investments	$224.66M-43.9%	$195.81M-64.8%	$509.01M+64.2%	$491.92M+29.7%	$400.21M-13.1%
Proceeds From Sale And Maturity Of Available For Sale Securities	$459.13M+22.8%	$486.03M+44.1%	$448.62M+30.8%	$445.82M+22.0%	$373.97M-18.5%
Proceeds From Purchase And Sale Agreement	——	$0-100%	$85.91M-66.7%	$171.83M0.0%	$257.74M+200%
Proceeds from issuance of common stock relating to employee stock plans	$1.53M-21.5%	$1.62M-5.7%	$1.65M+21.3%	$2.18M+102%	$1.95M+90.7%
Accounts Payable And Accrued Expenses	——	$0—	$0-100%	$0-100%	$0-100%
Lease Assets	——	$0-100%	$381K-66.7%	$762K0.0%	$1.14M+200%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Syndax Pharmaceuticals's cash flow data come from?: Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.